Cervical Cancer Diagnostics Global Market Report 2024

The cervical cancer diagnostics market size has grown strongly in recent years. It will grow from $8.89 billion in 2023 to $9.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed during the historical period can be attributed to factors such as heightened awareness and screening programs, the implementation of HPV vaccination, technological advancements, and an aging population.

The cervical cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $11.95 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth in the forecast period can be attributed to factors such as the rise in HPV-related cancers, the expansion of emerging markets, advancements in molecular testing, the adoption of telemedicine and remote screening. Key trends expected in the forecast period encompass increased HPV testing, the use of liquid-based cytology, automation and digital pathology, as well as the implementation of screen-and-treat programs.

The growing adoption of cervical cancer diagnostic tests to facilitate early detection is poised to propel the cervical cancer diagnostics market. The increased awareness among women about cervical cancer, along with the initiatives by global cancer organizations and governments to promote early testing for cervical cancer detection and prevention, significantly contributes to market growth. For example, a report from the National Cancer Institute in August 2023 revealed that in 2021, 72.4% of women aged 21 to 65 had undergone cervical cancer screening. The rising adoption of diagnostic tests and the focus on early diagnosis collectively drive the expansion of the cervical cancer diagnostics market.

The primary types of cervical cancer diagnostics include pap smear tests, HPV tests, colposcopy, biopsy, endocervical curettage, and other diagnostic procedures. A pap smear test is a method used for the detection of cervical cancer in women. This diagnostic process encompasses age groups such as those under 21, those aged 21 to 29, those aged 30 to 65, and those over 65. These diagnostics are utilized by various end-users, including hospitals, specialty clinics, cancer and radiation therapy centers, as well as diagnostic centers.

The cervical cancer diagnostics market research report is one of a series of new reports that provides cervical cancer diagnostics market statistics, including cervical cancer diagnostics industry global market size, regional shares, competitors with a cervical cancer diagnostics market share, detailed cervical cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer diagnostics industry. This cervical cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The increasing prevalence of cervical cancer is anticipated to be a key driver of growth in the cervical cancer diagnostics market. Cervical cancer, originating in the cervix, the narrow lower portion of the uterus, is a serious health concern. Diagnostic tests for cervical cancer play a pivotal role in early detection, accurate diagnosis, and effective treatment. For instance, estimates from Cancer.net, the patient information website of the American Society of Clinical Oncology (ASCO), suggest that approximately 13,960 women in the United States will be diagnosed with invasive cervical cancer. Consequently, the rising incidence of cervical cancer is expected to underpin the growth of the cervical cancer diagnostics market.

The increased utilization of HPV vaccination is likely to act as a hindrance to the cervical cancer diagnostics market. Two types of HPV (16 and 18) are responsible for 70% of cervical cancers and precancerous cervical lesions. The HPV vaccine has demonstrated its effectiveness in reducing the occurrence of precancerous cervical lesions that can progress to cervical cancer. In September 2022, a study published in Cancer Epidemiology, Biomarkers & Prevention indicated that one dose of the vaccine is sufficient for significantly reducing the risk of cervical cancer. Hence, the widespread adoption of HPV vaccination is predicted to impede the cervical cancer diagnostics market.

The emerging trend in the market is the increased adoption of HPV home testing kits, offering a convenient way for women to collect samples and obtain results without the need to visit a laboratory for screening. Companies are focusing on providing this convenience to patients. For instance, in September 2022, Mylab Discovery Solutions introduced the 'PathoDetectTM HPV PCR Detection Kit (Type 16/18),' which is a home testing kit for the detection of HPV types 16 and 18.

Leading companies in the cervical cancer diagnostics market are driving innovation with products like the Genius Digital Diagnostics System to enhance their market competitiveness. The Genius Digital Diagnostics System is a healthcare technology system designed for a range of diagnostic and clinical applications. For example, Hologic, Inc., a US-based health technology company, launched the Genius Digital Diagnostics System in Europe in November 2021. This system leverages advanced volumetric imaging technology and deep learning-based artificial intelligence (AI) to detect pre-cancerous lesions and cervical cancer cells in women during cervical cancer screening.

In February 2022, BD (Becton, Dickinson, and Company), a manufacturer of medical devices and reagents, acquired Cytognos for an undisclosed amount. BD's acquisition of Cytognos strengthens its commitment to chronic disease management, expanding its diagnostic portfolio, immune assessment tests, and informatics to gain deeper insights into the immune system, immune response, and Minimal Residual Disease (MRD). Cytognos, a Spain-based company, specializes in providing clinical flow cytometry solutions used in cervical cancer diagnostics.

Major companies operating in the cervical cancer diagnostics market include Abbott Laboratories, Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Zilico Ltd., Guided Therapeutics Inc., Thermo Fisher Scientific Inc., Carl Zeiss AG, OncoHealth Corporation, Arbor Vita Corporation, Micromedic Technologies Ltd., Trovagene Inc., Roche Diagnostics, Nucleix Ltd., BGI Genomics Co. Ltd., Cepheid, Exact Sciences Corporation, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., PerkinElmer Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation

North America was the largest region in the cervical cancer diagnostics market in 2023 Asia-Pacific was the second largest region in the cervical cancer diagnostics market. The regions covered in the cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cervical cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The cervical cancer diagnostics market consists of sales of analyzer, reagents, and others that are used for the diagnosis of cervical cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.